[ CAS No. 117009-97-9 ] {[proInfo.proName]}

Name: 117009-97-9|Benzyl 1,4-diazepane-1-carboxylate|95%
Brand: Ambeed
SKU: A905737
Price: 20.0 USD
Availability: InStock
Rating: 97 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 117009-97-9

Structure of 117009-97-9 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 117009-97-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 117009-97-9 ]

SDS Specification

Alternatived Products of [ 117009-97-9 ]

Product Details of [ 117009-97-9 ]

CAS No. :	117009-97-9	MDL No. :	MFCD01863703
Formula :	C₁₃H₁₈N₂O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	BXDQJVDEALOIQW-UHFFFAOYSA-N
M.W :	234.29	Pubchem ID :	4384955
Synonyms :

Calculated chemistry of [ 117009-97-9 ] Expand+

Physicochemical Properties

Num. heavy atoms :	17
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.46
Num. rotatable bonds :	4
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	73.34
TPSA :	41.57 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.79 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.63
Log Po/w (XLOGP3) :	1.32
Log Po/w (WLOGP) :	0.71
Log Po/w (MLOGP) :	1.41
Log Po/w (SILICOS-IT) :	1.59
Consensus Log Po/w :	1.53

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.12
Solubility :	1.77 mg/ml ; 0.00756 mol/l
Class :	Soluble
Log S (Ali) :	-1.79
Solubility :	3.77 mg/ml ; 0.0161 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-3.27
Solubility :	0.125 mg/ml ; 0.000532 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.37

Safety of [ 117009-97-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 117009-97-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 117009-97-9 ]

[ 117009-97-9 ] Synthesis Path-Downstream 1~96

1
[ 539-74-2 ]
[ 117009-97-9 ]
[ 336191-56-1 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

2
[ 36239-09-5 ]
[ 117009-97-9 ]
[ 336191-60-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

3
[ 655-32-3 ]
[ 117009-97-9 ]
[ 868066-28-8 ]

Yield	Reaction Conditions	Operation in experiment
100%	With triethylamine; In dimethyl sulfoxide; at 100℃; for 16h;	General procedure: 4-Fluorobenzonitrile (1.21 g, 10.0 mmol), 1-(tert-butoxycarbonyl)homopiperazine (1.96 mL, 10.0 mmol) and triethylamine (1.53 mL, 11.0 mmol) were dissolved in dimethylsulfoxide (20 mL) and the mixture was stirred at 100 C for 16 h. After cooling to room temperature, the mixture was diluted with ethyl acetate, washed successively with water and brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/ethyl acetate, 2:1) to give the title compound (1.90 g, 63%) as pale yellow oil.

Reference： [1]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 1628 - 1642
[2]Chemistry Letters,2006,vol. 35,p. 1090 - 1091

4
[ 117009-97-9 ]
4-{4-[(benzyloxy)carbonyl]-1,4-diazepan-1-yl}benzoic acid [ No CAS ]

Reference： [1]Chemistry Letters,2006,vol. 35,p. 1090 - 1091
[2]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 1628 - 1642

5
[ 117009-97-9 ]
[ 336191-57-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

6
[ 117009-97-9 ]
[ 336191-61-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

7
[ 117009-97-9 ]
[ 336191-58-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

8
[ 117009-97-9 ]
[ 336191-62-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

9
[ 117009-97-9 ]
3-[4-(2-pyridin-4-yl-2,8-diaza-spiro[4.5]decane-8-carbonyl)-[1,4]diazepan-1-yl]-propionic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

10
[ 117009-97-9 ]
[ 336191-59-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

11
[ 117009-97-9 ]
3-oxo-3-(4-[2-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-8-yl]carbonyl}-1,4-diazepan-1-yl)-propanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

12
[ 117009-97-9 ]
[ 336191-63-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 1103 - 1107

13
[ 1489-69-6 ]
[ 117009-97-9 ]
benzyl 4-(cyclopropylmethyl)homopiperazin-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tris(acetoxy)borohydride; acetic acid; In tetrahydrofuran; at 20℃; for 2h;	Benzyl 1-homopiperazinecarboxylate (1.95 g, 8.32 mmol) and cyclopropanecarboxyaldehyde (700 mg, 10.0 mmol) were dissolved in 40 mL of tetrahydrofuran. Acetic acid (600 mg, 10.0 mmol) and sodium triacetoxyborohydride (2.11 g, 10.0 mmol) were added thereto, and the reaction mixture was stirred at room temperature for two hours. The reaction mixture was mixed with 1 N aqueous solution of sodium hydroxide, extracted with ethyl acetate twice, and the combined organic layers were washed with brine once. The mixture was dried over anhydrous sodium sulfate and evaporated. The resulting residue was purified by silica gel column chromatography (Fuji Silysia, NH Silica gel; ethyl acetate:hexane=50:50) to give benzyl 4-(cyclopropylmethyl)homopiperazin-1-carboxylate (2.5 g) as a colorless oil. The resulting benzyl 4-(cyclopropylmethyl)homopiperazin-1-carboxylate (2.5 g) was dissolved in 50 mL of ethanol, 10% palladium-carbon (500 mg) was added, and the reaction mixture was stirred at room temperature under hydrogen atmosphere (1 atm) for 12 hours. The palladium-carbon was removed by filtration, and the filtrate was evaporated to give the title compound (1.4 g) as a colorless oil.1H-NMR Spectrum (CDCl3,400MHz) delta(ppm): 0.08-0.15(2H,m), 0.47-0.56(2H,m),0.82-0.95(1H,m),1.80-1.89(2H,m),2.44 (2H,d,J=6.4Hz) 2.75-2.85(4H,m),2.94-3.03(4H,m).

Reference： [1]Patent: EP1508570,2005,A1 .Location in patent: Page/Page column 135

14
[ 55552-69-7 ]
[ 117009-97-9 ]
[ 336191-60-7 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane;	Step A Preparation of Benzyl 4-(3-ethoxy-3-oxopropanoyl)-1,4-diazepane-1-carboxylate A mixture of N-Cbz-homopiperazine (4.268 mMol) and DIEA (8.60 mMol) in CH2Cl2 (15.0 mL) at 0 C. was treated with ethyl malonyl chloride (5.077 mMol). The solution was stirred at room temperature overnight. The reaction mixture was then partioned between CH2Cl2 and NaHCO3. The title compound was obtained by evaporation of the CH2Cl2 extract. It was purified by flash chromatography (91%).

Reference： [1]Patent: US2003/55244,2003,A1

15
[ 505-66-8 ]
[ 501-53-1 ]
[ 117009-97-9 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydrogencarbonate; In N-methyl-acetamide; water;	REFERENCE EXAMPLE 25 N-Benzyloxycarbonylhomopiperazine To 230 ml of dimethylformamide were added 25 g of homopiperazine and 5.4 g of sodium bicarbonate and then 25 ml of water followed by dropwise addition of 10 g of benzyloxycarbonyl chloride with stirring under ice cooling, and the mixture was stirred at a room temperature overnight. After evaporating off dimethylformamide under a reduced pressure, the reaction mixture was extracted three times with 100 ml of chloroform, and the extract was dried over magnesium sulfate and evaporated to remove the solvent under a reduced pressure. The resulting residue was applied to a silica gel column and eluted with chloroform/methanol (9:1), to obtain 9 g of the title compound as a light yellow liquor liquid. IR (KBr) cm-1: 1695, 1420; 1 H-NMR (CDCl3, delta ppm): 1.8 (2H, m), 2.8-3.0 (4H, m), 3.4-3.65 (4H, m), 5.15 (2H, s), 7.4 (5H, s).

Reference： [1]Patent: US5081246,1992,A

16
[ 67-64-1 ]
[ 117009-97-9 ]
[ 1035271-68-1 ]

Yield	Reaction Conditions	Operation in experiment
99%	With sodium tris(acetoxy)borohydride; acetic acid; at 20℃; for 18h;Product distribution / selectivity;	Sodium triacetoxyborohydride (5.79 g, 27.32 mmol) was added portionwise to <strong>[117009-97-9]benzyl 1,4-diazepane-1-carboxylate</strong> (2.56 g, 10.93 mmol) and acetic acid (1.251 mL, 21.85 mmol) in acetone (5.00 mL) at room temperature. The resulting solution was stirred at ambient temperature for 18 h under nitrogen. The reaction mixture was concentrated and diluted with water (200 mL) and basified with 2M NaOH. The aqueous was extracted with diethyl ether (3×100 mL) and washed sequentially with water (200 mL) and saturated brine (200 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford the desired product (3.00 g, 99%). This was used directly with no further purification. 1H NMR (399.9 MHz, DMSO-d6) delta 0.92-0.95 (6H, m), 1.63-1.69 (2H, m), 2.60 (2H, t), 2.80-2.88 (1H, m), 3.38-3.45 (4H, m), 5.09 (2H, s), 7.29-7.40 (5H, m), one (2H, m) obscured by solvent peak. MS: m/z 277 (MH+).

Reference： [1]Patent: US2008/153812,2008,A1 .Location in patent: Page/Page column 153

17
[ 505-66-8 ]
[ 13139-17-8 ]
[ 117009-97-9 ]

Reference： [1]Tetrahedron Letters,2008,vol. 49,p. 5047 - 5049

18
[ 871917-43-0 ]
[ 117009-97-9 ]
[ 1078061-72-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4968 - 4971

19
[ 117009-97-9 ]
[ 486460-00-8 ]
[ 1006706-47-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 6525 - 6529

20
[ 40411-25-4 ]
[ 117009-97-9 ]
C₂₂H₂₇N₃O₃ [ No CAS ]

Reference： [1]Organic Letters,2009,vol. 11,p. 5134 - 5137
[2]Chemistry - A European Journal,2013,vol. 19,p. 9343 - 9350

21
[ 3173-56-6 ]
[ 117009-97-9 ]
C₂₁H₂₅N₃O₃ [ No CAS ]

Reference： [1]Organic Letters,2009,vol. 11,p. 5134 - 5137
[2]Chemistry - A European Journal,2013,vol. 19,p. 9343 - 9350

22
[ 117009-97-9 ]
[ 1609-86-5 ]
C₁₈H₂₇N₃O₃ [ No CAS ]

Reference： [1]Organic Letters,2009,vol. 11,p. 5134 - 5137
[2]Chemistry - A European Journal,2013,vol. 19,p. 9343 - 9350

23
[ 102191-92-4 ]
[ 117009-97-9 ]
[ 1194373-98-2 ]

Yield	Reaction Conditions	Operation in experiment
51%		4 A Molecular sieves were added to a mixture of <strong>[117009-97-9]benzyl 1-homopiperazinecarboxylate</strong> (1.06 mL, 5.12 mmol), 2-(tert-butyldimethylsilyloxy)acetaldehyde (0.744 mL, 6.15 mmol), methanol (5 mL), and DCM (5 mL). After stirring for 20 minutes, the mixture was added to a solution of sodium triacetoxyborohydride (2.71 g, 12.80 mmol) in tetrahydrofuran (10 mL) and stirred for 1 hour. The reaction mixture was added to a saturated NaHCO3 solution (100 mL) and extracted with DCM. The organic extracts were combined, concentrated onto silica under reduced pressure and purified with silica chromatography (0-20% MeOH in EtOAc) to give 1.02 g (51 %) benzyl 4-(2-(te/t-butyldimethylsilyloxy)ethyl)-l,4-diazepane-l- carboxylate as a clear oil. m/z 393.A mixture of benzyl 4-(2-(ter£-butyldimethylsilyloxy)ethyl)-l,4-diazepane-l- carboxylate (1.02 g, 2.60 mmol) and palladium on carbon (0.083 g, 0.78 mmol) in methanol (10 mL) was stirred for 20 hours under hydrogen gas. The reaction mixture was filtered and concentrated under reduced pressure to give 0.66g (98 %) of a colorless oil. 1H NMR: 3.63 (t,2 H), 2.74 (t, 2 H), 2.67 (m, 4 H), 2.57 (m, 4 H), 1.61 (m, 2 H), 0.86 (s, 9 H), 0.03 (s, 6 H); m/z 259

Reference： [1]Patent: WO2009/136191,2009,A1 .Location in patent: Page/Page column 96

24
[ 1231948-59-6 ]
[ 1231948-60-9 ]
[ 117009-97-9 ]
[ 1231948-62-1 ]
[ 1307298-14-1 ]

Yield	Reaction Conditions	Operation in experiment
		Synthesis of 4-(1-chloro-8-propoxy-isoquinoline-5-sulfonyl)-<strong>[117009-97-9][1,4]diazepane-1-carboxylic acid benzyl ester</strong> (7) A solution of 1-chloro-8-propoxy-isoquinoline-5-sulfonic acid (5) and 1-chloro-8-propoxy-isoquinoline-7-sulfonic acid (6) (476 mg, 1.58 mmol) in SOCl2 (5 ml) and DMF (0.5 ml) was heated at 80 C for 2 h. The solvent was evaporated. The residue was quenched with H2O and the solution was neutralized (pH = 8) by addition of a saturated NaHCO3 solution. The mixture was extracted with CH2Cl2. The combined organic layers were poured drop wise to a solution of Cbz-homopiperazine (490 mg, 2.09 mmol) in CH2Cl2 (5 ml) at 0 C. The reaction was stirred at 0 C for 2 h. The reaction was washed with water. The organic layers were dried over MgSO4, concentrated and purified by flash chromatography (cyclohexane/EtOAc 10/0 to 8/2) to afford 360 mg (44%) of 4-(1-chloro-8-propoxy-isoquinoline-5-sulfonyl)-<strong>[117009-97-9][1,4]diazepane-1-carboxylic acid benzyl ester</strong> (7) as a yellow oil. 1H NMR (300 MHz,DMSO-d6) delta : 8.37-8.18 (m, 3H), 7.25 (m, 5H), 6.91 (d, J = 8.6 Hz, 1H), 5.02 (s, 2H), 4.13 (t, J = 6.1 Hz, 2H), 3.54-3.46 (m, 4H), 3.36-3.27 (m, 4H), 1.97-1.80 (m, 4H), 1.19 (t, J = 7.1 Hz, 3H).

Reference： [1]Patent: EP2332917,2011,A1 .Location in patent: Page/Page column 9

25
[ 117009-97-9 ]
[ 1334232-85-7 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 8325 - 8328

26
[ 117009-97-9 ]
C₁₃H₁₇ClN₂O₂ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 8325 - 8328

27
[ 1425051-59-7 ]
[ 117009-97-9 ]
[ 1425051-04-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1253 - 1256

28
[ 117009-97-9 ]
[ 1428556-50-6 ]